Eli Lilly schizophrenia drug doesn´t meet its expectations

According to recent news, Eli Lilly´s drug for the treatment of schizophrenia, Pomaglutemad Methionil, has not covered the objective of the first of the two programmed Phase III clinical studies.

The company expected this drug not to show the secondary effects seen for other schizophrenia drugs, such as gain of weight and irregularities in reproductive hormones.

Be Sociable, Share!